NCT02066675 - Trabectedin First Line Therapy In Unfit Sarcoma Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to ReceiveStandard Chemotherapy

Interventions

DRUG

Trabectedin

Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks

Trial Locations (16)

I.R.C.C. - Unit of Medical Oncology, Candiolo

Presidio Sanitario Gradenigo, Torino

Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna

Ospedali Riuniti di Bergamo, Bergamo

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola

Ospedale Galliera, Genova

IRCCS Azienda Ospedaliera Universitaria San Martino IST, Genova

Ospedale Villa Scassi, Genova

"Ospedale Misericordia e Dolce Istituto Toscano Tumori, Azienda USL4", Prato

"A.S.O. SS Antonio e Biagio e Cesare Arrigo", Alessandria

Ospedale SS. Trinità di Sora, Frosinone

IST, Genova

Policlinico Federico II Napoli, Napoli

Istituto Oncologico Veneto, Padua

Ospedale Giaccone, Palermo

Campus Biomedico, Roma

All Listed Sponsors

lead

Italian Sarcoma Group

NETWORK